Phase IIb Clinical Study to Assess the Safety and Efficacy of CN128 Tablets in the Treatment of Iron Overload in Transfusion Dependent Thalassemia With Sever Liver Iron Overloaded Patients Aged 16 and Above
Latest Information Update: 20 Mar 2025
At a glance
- Drugs CN 128 (Primary)
- Indications Iron overload
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Hangzhou Zede Pharmaceutical Technology
Most Recent Events
- 14 Mar 2025 Status changed from recruiting to completed.
- 27 Feb 2024 Planned End Date changed from 31 Mar 2024 to 31 Dec 2024.
- 27 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Oct 2024.